Skip to main content

""

Completed Private
Sector Projects

The following private sector projects have been completed.

Client: Shoppers Drug Mart

Research Question/Objectives: An average 50% of patients with chronic disease discontinue their medication within the first year. Non-adherence accounts for 5% of hospitalizations and $7-9B in health care costs. This study aims to understand what factors contribute to adherent/non-adherent behaviour, to inform future work examining whether targeted incentives can lead to improved adherence and preventative health management in Ontario for 2016. Over the longer term, there is interest to see whether these incentives translate to improved health outcomes (i.e. lower health care utilization or hospitalizations). The practice of offering incentives is not currently permitted in Ontario. Specifically, the research questions of interest are:

  • Identify the variables associated with medication adherence among the study population. Results will identify risk factors of non-adherence, and will inform inclusion and exclusion criteria for Phase 2
  • Explore the relationship between medication adherence, health outcomes and health care utilization among the study population.

Availability of Results: June 2018


Client: Sanofi Pasteur

Research Question/Objectives: The objective of this research is to utilize linked health administrative databases in Ontario to establish the burden of Clostridium difficile (CDI) in Canada’s most populous province. Through the use of descriptive statistics, regression modeling and matched case-control analysis, this study will answer important questions about CDI which are necessary for optimal decision-making regarding prevention and treatment planning. Specifically , the research questions of interest are:

  • To measure the annual incidence of CDI in Ontario, both overall and in acute care hospitals, long-term care facilities, and community-dwelling populations 
  • To determine the complication rates associated with CDI in these populations, compared to control groups with similar demographics and medical history 
  • To estimate the cost of health care utilization associated with CDI in Ontario.

Availability of Results: April 2019


Client: imshealth | brogan

Research Question/Objectives: Hypoparathyroidism is a rare disease as noted by NORD and typically is caused by damage to the parathyroid during head and neck surgery. Treatment is chronic and consists of vitamin D and calcium supplements. In contrast to hyperparathyroidism, hypoparathyroidism is not well studied, and only five prevalence studies have been published outside of Canada. This study aims to understand the epidemiology and burden of hypoparathyroidism in Ontario. Specifically, the research questions of interest are:

  • What is the prevalence, incidence, and burden of illness of hypoparathyroidism in Ontario?
  • What treatments are received by hypoparathyroidism patients in Ontario?
  • What are the costs and resource utilization of Ontarians with hypoparathyroidism?

Availability of Results: September 2019


Client: imshealth | brogan

Research Question/Objectives: Ulcerative colitis and Crohn’s disease are the most prevalent types of inflammatory bowel diseases (IBD), with etiologies rooted in a complex interplay of genetic, microbial, and environmental factors. The overall objective of this retrospective study is to estimate the health care resource utilization and direct medical costs associated with Crohn’s disease and ulcerative colitis patients, when treated with biologic therapies, and compare the difference by type of index biologic used. Specifically, the research objectives of interest are:

  • Determine the health care resource utilization and direct medical cost of IBD study patient cohort treated with a biologic and retained on it for at least 24 months, compared to a non-IBD cohort.
  • Determine the occurrence of disease specific health outcomes for an IBD study patient cohort treated with a biologic and retained on it for at least 24 months, compared to a non-IBD cohort.
  • Estimate and describe the proportion of patients that are primary non-responders and primary responders.

Availability of Results: September 2019



×